Protection against post-ischemic behavioral pathology by the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) in the gerbil

Neurosci Lett. 1991 Dec 9;133(2):291-4. doi: 10.1016/0304-3940(91)90591-g.

Abstract

The neuroprotective effects of NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline) were assessed on hippocampal CA1 neuronal loss and locomotor hyperactivity following transient bilateral carotid artery occlusion (BCAO) in the gerbil. NBQX, a selective blocker of the AMPA glutamate receptor subtype, was injected 1 h after 5 or 10 min BCAO, or sham surgery. Both 5 and 10 min ischemia produced equivalent hyperactivity 3 days post ischemia and CA1 neuronal loss on Day 4, while activity was unchanged in the sham-operated group. NBQX protected from both hippocampal damage and post-ischemic hyperactivity. These results demonstrate that NBQX can protect from behavioral pathology induced by global cerebral ischemia.

MeSH terms

  • Animals
  • Gerbillinae
  • Hippocampus / drug effects
  • Hippocampus / pathology*
  • Hippocampus / physiopathology
  • Ischemic Attack, Transient / drug therapy
  • Ischemic Attack, Transient / pathology
  • Ischemic Attack, Transient / physiopathology*
  • Male
  • Motor Activity / drug effects*
  • Neurons / drug effects
  • Neurons / pathology*
  • Neurons / physiology
  • Pyramidal Tracts / drug effects
  • Pyramidal Tracts / pathology*
  • Pyramidal Tracts / physiopathology
  • Quinoxalines / pharmacology*
  • Quinoxalines / therapeutic use
  • Receptors, AMPA
  • Receptors, Neurotransmitter / antagonists & inhibitors*

Substances

  • Quinoxalines
  • Receptors, AMPA
  • Receptors, Neurotransmitter
  • 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline